Retatrutide vs Tirzepatide for Appetite Suppression
Tirzepatide is a dual agonist. Retatrutide is a triple agonist. Does the extra receptor target translate to better appetite control? Here is what the data shows.
Medical Disclaimer: Retatrutide is an investigational medication. This comparison is based on available clinical trial data and is for informational purposes only.
The evolution from single agonist (semaglutide) to dual agonist (tirzepatide) to triple agonist (retatrutide) represents a progression in how aggressively these medications target the biological drivers of obesity. But more targets does not always mean better results.
Different Mechanisms, Different Appetite Effects
Tirzepatide (GLP-1 + GIP): Reduces appetite through GLP-1 receptor activation in the hypothalamus and brainstem. The GIP component enhances insulin response and may modulate fat metabolism. Appetite suppression is the primary driver of weight loss.
Retatrutide (GLP-1 + GIP + Glucagon): Shares tirzepatide's appetite-suppressing mechanisms but adds glucagon receptor activation. Glucagon increases hepatic glucose output, energy expenditure, and thermogenesis. This means retatrutide works on both sides: reducing intake AND increasing calorie burning.
What the Clinical Data Shows
| Metric | Tirzepatide (15mg) | Retatrutide (12mg) |
|---|---|---|
| Weight loss (max dose) | 22.5% (72 weeks) | 24.2% (48 weeks) |
| Patients losing 15%+ | ~63% | ~93% |
| Weight loss still trending down | Plateauing by 72 weeks | Still declining at 48 weeks |
The fact that retatrutide achieved 24% weight loss in only 48 weeks (compared to tirzepatide's 22.5% in 72 weeks) suggests either stronger appetite suppression, greater energy expenditure, or both.
Practical Considerations
- Availability: Tirzepatide is FDA-approved and available now. Retatrutide is still in Phase 3 trials
- Long-term data: Tirzepatide has years of real-world data. Retatrutide has only Phase 2 trial data
- Cost: Tirzepatide is available as compounded medication ($125/mo through Trimi). Retatrutide pricing is not yet established for brand-name
- Side effect profile: Similar GI side effects. Retatrutide's glucagon component may affect heart rate
The Bottom Line
Our Assessment
Retatrutide appears to have a slight edge in appetite suppression and weight loss, but the comparison is preliminary. Tirzepatide remains an excellent choice with proven results and current availability. For patients who plateau on tirzepatide, retatrutide may eventually offer a next step.
Frequently Asked Questions
Which suppresses appetite more — retatrutide or tirzepatide?
Both produce profound appetite suppression. Retatrutide's Phase 2 trial showed 24% weight loss vs tirzepatide's 22%, suggesting slightly greater appetite effects. The glucagon component in retatrutide may also increase energy expenditure, contributing to additional weight loss beyond appetite suppression alone.
Does retatrutide work through a different appetite mechanism than tirzepatide?
Yes. Tirzepatide activates GLP-1 and GIP receptors to reduce appetite. Retatrutide adds glucagon receptor activation, which increases energy expenditure and thermogenesis. So retatrutide works on both sides of the energy equation: eating less AND burning more.
Will I lose my appetite completely on retatrutide?
Neither medication eliminates appetite entirely. They reduce hunger signals and increase satiety. You will still feel some hunger, especially at lower doses. At higher doses, some patients report near-complete loss of food interest, which is why adequate nutrition (especially protein) is important.
Can I switch from tirzepatide to retatrutide for more appetite suppression?
Potentially, once retatrutide becomes widely available. Discuss with your provider whether the incremental benefit justifies switching. Some patients who plateau on tirzepatide may benefit from retatrutide's additional glucagon mechanism.
Explore All Options with Trimi
Semaglutide ($99/mo), tirzepatide ($125/mo), and retatrutide options available. Our clinicians match you with the right medication.
Get Started TodayMore on Micro-Comparisons
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).